Jonathan Parr, MD, MPH, wrote an editorial that was published in the October 20, 2020 issue of JAMA Internal Medicine.
The editorial — titled “Time to Reassess Tocilizumab’s Role in COVID-19 Pneumonia” — reviews recently released randomized trials and concludes that the results “do not support the routine use of tocilizumab for COVID-19 in most settings.”